Navigation Links
Robert Avery, D.O., M.S.C.E., studies innovations to improve vision in children with tumors
Date:2/28/2014

Robert Avery, DO, MSCE, of Children's National Health System and colleagues are establishing innovative approaches with technology and medication to improve the vision of young children who have visual pathway glioma, a type of brain tumor.

Most optic pathway gliomas cause vision loss in children between one and eight years of age. As many as 20 percent of children with neurofibromatosis type 1 -- a genetic disorder that occurs in 1 in every 4,000 births may develop these tumors. It is estimated that nearly half of those children may experience vision problems from their tumors.

Optic pathway gliomas can also occur sporadically, and not be related to neurofibromatosis type 1. Vision loss from these tumors can range from mild to complete blindness, and may be permanent if not properly treated. Unfortunately, standard treatment with front line chemotherapy typically results in modest improvements or stabilization of their vision.

Using Medications

In their study published in JAMA Ophthalmology, Avery and his colleagues report on four children with optic pathway gliomas that demonstrated marked recovery of vision when treated with the medication Bevacizumab. Other Children's National researchers included Roger J. Packer, MD, Senior VP of the Center for Neurosciences and Behavioral Medicine, and Eugene I. Hwang, MD, a neuro-oncologist.

Bevacizumab is an angiogenesis inhibitor, a drug that slows the growth of new blood vessels, to treat various cancers.

Bevacizumab provides a fast, robust response in these children," Avery told Reuters Health. "Although it's not first-line treatment, Bevacizumab is a good alternative or adjunct treatment."

Dr. Avery and colleagues identified children who had recovery of visual acuity or visual field in treatment with Bevacizumab.

A nine-year-old girl's visual acuity improved from 20/400 to 20/100 within six weeks of Bevacizumab treatment and remained stable for nine months after the treatment was discontinued, Avery wrote. Her visual field improved after two months of Bevacizumab monotherapy and her visual acuity returned to normal after four months of therapy. It remained stable at 12 months.

The standard front line treatment using cardioplatin-based chemotherapy typically produces only a modest benefit in visual acuity, Avery says.

"Given that most patients with OPG-related visual impairment will show modest or no visual improvement with standard treatment, the incorporation of Bevacizumab in these cases may greatly improve visual outcomes and should be considered in appropriate clinical situations," Avery says.

Handheld Technology

In another study in JAMA Ophthalmology Avery and other researchers found that using innovative technology, such as handheld optical coherence tomography (OCT), may help physicians improve their ability to evaluate children with optic pathway gliomas by capturing three-dimensional ultrahigh resolution (e.g., 3 microns..one-half the width of a red-blood cell) images or their retinal axons. Avery's study was also reported in Reuters Health.

In that study, the other Children's National researchers included Packer, Hwang, Maria T. Acosta, MD, in neurology, Domiciano Jerry Santos, MD, in anesthesiology, sedation, and perioperative medicine, Dina J. Zand, MD, PhD, in the genetics program, Lindsay B. Kilburn, MD, in neuro-oncology, Kenneth N. Rosenbaum, MD, in genetics and metabolism, and Brian R. Rood, MD, clinical director of the neuro-oncology program.

In very young children with these tumors, it may be difficult to measure visual acuity especially if they have cognitive or behavioral difficulties. "The handheld OCT provides a safe, non-contact and objective measure of visual pathway integrity that does not rely on a child's cooperation," Avery says.

"We hope that our handheld OCT measures will someday improve our ability to detect and monitor tumor progression that cannot be discovered during a routine eye exam or MRI scan," Avery adds.


'/>"/>

Contact: Joe Cantlupe
jcantlupe@childrensnational.org
202-476-4500
Children's National Medical Center
Source:Eurekalert

Related medicine news :

1. Amyotrophic Lateral Sclerosis Association honors Dr. Robert Baloh, M.D.
2. June 2012 marks a milestone for International Urogynecology Associates as Dr. Robert D. Moore and Dr. John R. Miklos perform their 24th Neovagina Surgery in 24 months
3. Crimmins earns GSAs 2012 Robert W. Kleemeier Award
4. NAI Fellows Robert Langer, Leroy Hood and Member James Wynne receive US National Medals
5. Dr. Robert Barr of Barr Family Dentistry in San Jose, CA Receives Top Reviews for Painless Laser Dental Procedures
6. Challenging Conventional Wisdom, Dr. John Miklos and Dr. Robert Moore Repair a Failed Omental Flap Vesicovaginal Fistula Laporoscopically and Without an Omental Flap
7. Washington, DC Plastic Surgeon Dr. Roberta L. Gartside Launches New Website
8. Healthesystems Appoints Dr. Robert L. Goldberg as Chief Medical Officer
9. Robert S. Shumake’s Climbing Your Inner Mountain Makes Amazon Hot New Release and Kindle Best Seller List
10. Aid and Attendance Seminar with Robert Hart at the Timbers of Shorewood
11. Robert Beshirs of Help The Dallas Homeless, LLC
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/26/2016)... ... June 27, 2016 , ... Quality metrics are proliferating in cancer care, ... remain in the eye of the beholder, according to experts who offered insights and ... Journal of Managed Care. For the full issue, click here . , For ...
(Date:6/26/2016)... ... June 26, 2016 , ... ... they have been diagnosed with endometriosis. These women need a treatment plan to ... a comprehensive approach that can help for preservation of fertility and ultimately achieving ...
(Date:6/25/2016)... ... June 25, 2016 , ... First Choice Emergency Room , the ... Ogunleye, as the Medical Director of its new Mesquite-Samuell Farm facility. , “We ... new Mesquite location,” said Dr. James M. Muzzarelli, Executive Medical Director of First Choice ...
(Date:6/24/2016)... CA (PRWEB) , ... June 24, 2016 , ... A ... procedures that most people are unfamiliar with. The article goes on to state that ... but also many of these less common operations such as calf and cheek reduction. ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... Global law ... magazine’s 2016 Legal Elite. The attorneys chosen by their peers for this recognition are ... , Seven Greenberg Traurig Shareholders received special honors as members of this year’s Legal ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... Research and Markets has announced the addition of the ... to 2022" report to their offering. ... financial data derived from varied research sources to present unique ... on the market during the next five years, including a ... markets, regional and country level analysis. The report provides a ...
(Date:6/23/2016)... 23, 2016 Research and Markets has ... 52" report to their offering. ... creates a favourable commercial environment for MedImmune to enter. The ... that will serve to drive considerable growth for effective anti-influenza ... to cap sales considerably, but development is still in its ...
(Date:6/23/2016)... June 23, 2016 , , ... July 7, 2016 , , , , LOCATION: , , ... , , , EXPERT PANELISTS:  , , , Frost & ... Analyst, Christi Bird; Senior Industry Analyst, Divyaa Ravishankar and Unmesh Lal, ... The global pharmaceutical industry is witnessing an exceptional era. Several new ...
Breaking Medicine Technology: